Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar;19(Suppl 1):S1-4.

Statin efficacy in the treatment of hepatitis C genotype I

Ahmad Shavakhi  1 , Mohamad Minakari  1 , Afshin Bighamian  1 , Sina Sadeghian  1 , Sara Shavakhi  2 , Naser Khamisi  1 , Mahsa Khodadustan  1 , Majid Talebi  1 , Behrooz Ataei  3
Affiliations

Statin efficacy in the treatment of hepatitis C genotype I

Ahmad Shavakhi et al. J Res Med Sci. 2014 Mar.

Abstract

Background: Lipid metabolism is one of the hepatitis C virus (HCV) life cycle steps. Statins can reduce cholesterol level and finally can decrease HCV replication. Thus, we assessed the effect of Statins in combination with standard antiviral treatment on hyperlipidemic genotype I HCV infected patients.

Materials and methods: This study was a prospective clinical trial. 40 patients were selected from those referred to educational and Therapeutic Centers of Isfahan University of Medical Sciences from 2009 to 2010 with confirmed HCV viremia. All patients received Peg-interferon-a2a and ribavirin. 20 hyperlipidemic Patients received 20 mg atorvastatin nightly for 3 months and placebo was prescribed for 20 normolipidemic HCV infected patients as a control group. Liver enzymes and complete blood count were checked monthly and thyroid stimulating hormone was checked every 3 months. We also performed quantitative HCV-ribonucleic acid (RNA) test in 12(th) week of therapy, at the end of treatment and 6 months after therapy for all samples.

Results: We didn't find any significant differences in the mean of HCV-RNA numbers between statin and placebo groups in 12(th) week of treatment, in the end of treatment and 6 months after treatment (P > 0.05).

Conclusion: Atorvastatin has no effect on the mean of HCV viral load when we added it to standard treatment for hepatitis C infection. Further studies are necessary to examine the possible antiviral properties of statins and their potential role as adjuncts to standard HCV therapy.

Keywords: Hepatitis C; hyperlipidemia; statins.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors have no conflict of interest.

References

    1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745–50. - PubMed
    1. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 2003;9:331–8. - PubMed
    1. Zhu Q, Li N, Han Q, Zhang P, Yang C, Zeng X, et al. Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: A systematic review and meta-analysis. Antiviral Res. 2013;98:373–9. - PubMed
    1. Vere CC, Streba CT, Streba L, Rogoveanu I. Statins in the treatment of hepatitis C. Hepat Mon. 2012;12:369–71. - PMC - PubMed
    1. Blanchet M, Seidah NG, Labonté P. SKI-1/S1P inhibition: A promising surrogate to statins to block hepatitis C virus replication. Antiviral Res. 2012;95:159–66. - PubMed